Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Medivir Rises on Plans for Hepatitis C Study: Stockholm Mover

Medivir AB, a Swedish biotech company, rose the most in eight months after announcing a mid-stage study for a hepatitis C treatment combining simeprevir with VX-135, developed by Vertex Pharmaceuticals Inc.

The shares rose as much as 12 percent, the biggest intraday gain since February, and were up 11 percent at 67.25 kronor as of 3:11 p.m.

The proof-of-concept study will start early next year to investigate tolerability, safety and viral cure rates after a 12-week period, Stockholm-based Medivir said today in a statement. Simeprevir, developed by Johnson & Johnson with Medivir, is a hepatitis C treatment now in late-stage studies and is also known as TMC435. VX-135 is designed to attack the hepatitis C virus in a different way, Medivir said.

“This study will broaden our understanding of simeprevir, which we believe has the necessary characteristics to become a key component of future hepatitis C treatment regimens,” Charlotte Edenius, who heads Medivir’s research and development department, said in the statement.

Johnson & Johnson and Vertex will share the costs for the study equally and there are no up-front or milestone payments connected to the agreement.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.